Stocktoria
Lantern Pharma Inc. LTRN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-06-11
Lantern Pharma Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D expense | $11.5M | $16.1M | $11.9M | $8.6M | $7.6M | $2.2M | — |
| Operating income | -$18.0M | -$22.2M | -$17.9M | -$14.4M | -$12.6M | — | — |
| Net income | -$17.1M | -$20.8M | -$16.0M | -$14.3M | -$12.4M | -$5.9M | -$2.4M |
| EPS (diluted) | $-1.57 | $-1.93 | $-1.47 | $-1.31 | — | — | — |
| Operating cash flow | -$15.7M | -$17.8M | -$14.3M | -$12.8M | -$10.6M | -$5.7M | -$2.1M |
| Free cash flow | -$15.7M | -$17.8M | -$14.4M | -$12.8M | -$10.6M | — | — |
| Cash & equivalents | $4.4M | $7.5M | $21.9M | $37.2M | $51.5M | $19.2M | $1.2M |
| Total assets | $11.0M | $25.6M | $43.6M | $58.8M | $74.0M | $20.4M | $1.4M |
| Total liabilities | $4.5M | $4.4M | $2.7M | $2.8M | $2.4M | $660,839 | $489,292 |
| Shareholders' equity | $6.5M | $21.2M | $40.9M | $56.0M | $71.6M | $19.7M | $943,284 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.